An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“blocking these receptors can result in profound muscle growth in animals and humans18–22”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [19]
In the citing paper
“Interestingly, STC2 is among the genes that are downregulated in skeletal muscle from mice following bimagrumab (activin type II receptor antagonist) treatment [149].”
From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [149]
In the citing paper
“Myostatin is secreted by the myocytes and inhibits their differentiation and proliferation.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Myostatin and Activin receptor type 2 (ActRII) inhibitors have been developed and shown to increase muscle mass and strength and as well as improve insulin sensitivity in vitro (94, 95).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Its level increased in individuals with sarcopenia and/or obesity.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“In addition to myostatin (5, 6), other negative regulators of muscle mass have been reported to signal through ActRIIB, including activin A (10–13), while some uncertainty with regard to the contribution of the closely related GDF11 at regulating muscle mass and function remains (13–15).”
BackgroundRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 3×
“Prior studies had suggested this as well (10, 18), but this is the first demonstration that an antibody directed at the ActRII receptor can induce significantly greater hypertrophy than myostatin inhibition alone; the point had been made with the ActRIIB trap, but that molecule can actually also bind other ligands tha…”
BackgroundRommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationMyostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940 · cited 3×
“Intervention at the ActRIIB pathway level under cancer cachexia conditions in mice showed a clear benefit not only for muscle preservation but also for overall survival, without affecting tumor growth (24).”
BackgroundInduction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
Research works printed but not linked: 1
- Glass D, 2010, Curr. Top. Microbiol. Immunol., 346, 267
Cited by
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
GDF11 increases with age and inhibits skeletal muscle regeneration
Egerman, M. A., Cadena, S. M., Gilbert, J. A., Meyer, A., Nelson, H. N., Swalley, S. E., Mallozzi, C., Jacobi, C., Jennings, L. L., Clay, I., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.010 · Cited by 527
“Even though we demonstrated similar direct signaling of GDF11 and myostatin and that this correlated to inhibitory effects by both molecules on the differentiation of human skeletal myoblasts, it was still formally possible that GDF11 might have some unique activity on muscle, distinct from its activation of ActRII/AL…”
InfluentialSelf-citationMechanisms of metabolic dysfunction in cancer-associated cachexia
Petruzzelli, M., & Wagner, E. F. (2016) · Genes & Development · doi:10.1101/gad.276733.115 · Cited by 340
“Furthermore, inhibition of ActRIIB by a humanized monoclonal antibody has been shown to increase skeletal muscle mass and prevent glucocorticoid-induced atrophy in mice (Lach-Trifilieff et al. 2014).”
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
“The clinical trial of another inhibitor, such as BYM338, which specifically inhibits myostatin and activin A, has been tested in a phase II clinical trial (NCT01925209, 2013), and GDF11 is now being considered in clinical trials [263, 270].”
BackgroundSarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
“Myostatin and Activin receptor type 2 (ActRII) inhibitors have been developed and shown to increase muscle mass and strength and as well as improve insulin sensitivity in vitro (94, 95).”
BackgroundPhage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
“Identification of high affinity HER2 binding antibodies using CHO Fab surface display.”
BackgroundInfluentialThe BMP Pathway and Its Inhibitors in the Skeleton
Lowery, J. W., & Rosen, V. (2018) · Physiological Reviews · doi:10.1152/physrev.00028.2017 · Cited by 250
Argilés, J. M., López-Soriano, F. J., Stemmler, B., & Busquets, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00734-5 · Cited by 246
Rooks, D., Praestgaard, J., Hariry, S., Laurent, D., Petricoul, O., Perry, R. G., Lach‐Trifilieff, E., & Roubenoff, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14927 · Cited by 244
“, myostatin, activin A).(4) These ligands normally act as inhibitors of muscle growth and protein anabolism; bimagrumab lifts this inhibition and can increase muscle mass in young and older adults.”
BackgroundSelf-citationSkeletal Muscle Wasting and Renewal: A Pivotal Role of Myokine IL-6
Belizário, J. E., Fontes-Oliveira, C. C., Borges, J. P., Kashiabara, J. A., & Vannier, E. (2016) · SpringerPlus · doi:10.1186/s40064-016-2197-2 · Cited by 244
Willems, S. M., Wright, D. J., Day, F. R., Trajanoska, K., Joshi, P. K., Morris, J. A., Matteini, A. M., Garton, F. C., Grarup, N., Oskolkov, N., et al. (2017) · Nature Communications · doi:10.1038/ncomms16015 · Cited by 220
Walker, R. G., Poggioli, T., Katsimpardi, L., Buchanan, S. M., Oh, J., Wattrus, S., Heidecker, B., Fong, Y. W., Rubin, L. L., Ganz, P., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308391 · Cited by 209
“Conversely, treatment of mice with the inhibitory myostatin propeptide induces muscle hypertrophy.(127)”
Muscle metabolism and atrophy: let’s talk about sex
Rosa-Caldwell, M. E., & Greene, N. P. (2019) · Biology of Sex Differences · doi:10.1186/s13293-019-0257-3 · Cited by 202
Sarcopenic obesity: Emerging mechanisms and therapeutic potential
Axelrod, C. L., Dantas, W. S., & Kirwan, J. P. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155639 · Cited by 204
Exercise-Induced Myokines With Therapeutic Potential for Muscle Wasting
Piccirillo, R. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00287 · Cited by 189
Pathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease
Hiatt, W. R., Armstrong, E. J., Larson, C. J., & Brass, E. P. (2015) · Circulation Research · doi:10.1161/circresaha.116.303566 · Cited by 187
Sarcopenia – The search for emerging biomarkers
Kalinkovich, A., & Livshits, G. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.05.001 · Cited by 187
“In addition, bimagrumab enhanced the differentiation of primary human skeletal myoblasts and counteracted the inhibition of differentiation induced by myostatin, and also prevented myostatin-induced atrophy through inhibition of Smad2/3 phosphorylation (Lach-Trifilieff et al., 2014).”
Activin A more prominently regulates muscle mass in primates than does GDF8
Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185
Rooks, D., Swan, T., Goswami, B., Filosa, L. A., Bunte, O., Panchaud, N., Coleman, L. A., Miller, R. R., Garcia Garayoa, E., Praestgaard, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20836 · Cited by 177
Self-citationTGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease
Sartori, R., Gregorevic, P., & Sandri, M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.06.002 · Cited by 177
Kwak, J. Y., & Kwon, K.-S. (2019) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.19.0028 · Cited by 171
The myostatin gene: an overview of mechanisms of action and its relevance to livestock animals
Aiello, D., Patel, K., & Lasagna, E. (2018) · Animal Genetics · doi:10.1111/age.12696 · Cited by 162
Reichert, J. M. (2014) · mAbs · doi:10.4161/19420862.2015.988944 · Cited by 156
“Bimagrumab targets type II activin receptors, which are involved in the regulation of muscle mass.(8) The on-going Phase 2/3 RESILIENT study (NCT01925209) is evaluating the efficacy, safety and tolerability of IV administration of multiple doses of bimagrumab compared to placebo on physical function, muscle strength,…”
BackgroundMuscle-bone interactions: From experimental models to the clinic? A critical update
Laurent, M. R., Dubois, V., Claessens, F., Verschueren, S., Vanderschueren, D., Gielen, E., & Jardí, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.10.017 · Cited by 163
“In preclinical models, this strategy prevented myostatin- and activin Ainduced as well as glucocorticoid-induced muscle atrophy, beyond the effects of sole myostatin inhibition by genetic or pharmacological means (Lach-Trifilieff et al., 2014).”
BackgroundSanders, K. J. C., Kneppers, A. E. M., van de Bool, C., Langen, R. C. J., & Schols, A. M. W. J. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12062 · Cited by 148
“kidney failure, pharmacological inhibition of MSTN blocks muscle atrophy,(109) and that pharmacological inhibition of the ActII-receptor, which mediates MSTN signalling, prevents glucocorticoid-induced muscle atrophy.(110) In vitro, glutamine”
BackgroundTargeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Lee, S.-J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148372 · Cited by 143
“Specifically, bimagrumab, which targets receptors used by both MSTN and activin A, showed increases of 25% to 50% in mice (48), and the ACVR2B/Fc decoy receptor, which can act as a ligand trap for both MSTN and activin A, showed increases of over 50% in mice (33).”
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?
Hilmi, M., Jouinot, A., Burns, R. G., Pigneur, F., Mounier, R., Gondin, J., Neuzillet, C., & Goldwasser, F. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.003 · Cited by 162
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
“Both agents also prevented muscle wasting in several disease models, ranging from glucocorticoid-induced atrophy (28) to cancer cachexia (26, 29), as indeed myostatin and activin A had been reported to induce muscle wasting and cachexia (5, 6, 30).”
BackgroundResultInfluentialSelf-citationHanna, M. G., Badrising, U. A., Benveniste, O., Lloyd, T. E., Needham, M., Chinoy, H., Aoki, M., Machado, P. M., Liang, C., Reardon, K. A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30200-5 · Cited by 138
Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., Calhoun, R., Lee, M., Holman, C. D., Baur, J. A., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101880 · Cited by 126
Sarcopenia in chronic liver disease: mechanisms and countermeasures
Allen, S., Quinlan, J. I., Dhaliwal, A., Armstrong, M. J., Elsharkawy, A. M., Greig, C. A., Lord, J. M., Lavery, G. G., & Breen, L. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00373.2020 · Cited by 144
Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer
Gallot, Y. S., Durieux, A.-C., Castells, J., Desgeorges, M. M., Vernus, B., Plantureux, L., Rémond, D., Jahnke, V. E., Lefai, E., Dardevet, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0057 · Cited by 117
Chen, J. L., Walton, K. L., Hagg, A., Colgan, T. D., Johnson, K., Qian, H., Gregorevic, P., & Harrison, C. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620013114 · Cited by 116
Supraphysiological levels of GDF 11 induce striated muscle atrophy
Hammers, D. W., Merscham‐Banda, M., Hsiao, J. Y., Engst, S., Hartman, J. J., & Sweeney, H. L. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607231 · Cited by 115
“For ActRIIB antibody (antiActRIIB) assays, HEK293T cells were treated with 0 or 100 nM antiActRIIB (Creative BioMart, murinized version of BYM338 antibody; Lach-Trifilieff et al, 2014) overnight prior to ligand addition, lysing, and AlphaLISA evaluation, as described above.”
MethodMyostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Polkey, M. I., Praestgaard, J., Berwick, A., Franssen, F. M. E., Singh, D., Steiner, M. C., Casaburi, R., Tillmann, H.-C., Lach-Trifilieff, E., Roubenoff, R., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0286oc · Cited by 111
“Bimagrumab, an ActRII blocker, has been shown to cause substantial skeletal muscle hypertrophy in animal models (17) and humans (18) by preventing the activity of myostatin and other negative regulators of muscle mass in a SMAD 2/3 (small mothers against decapentaplegic 2/3; the main signal transducers for ActRII)–dep…”
BackgroundSelf-citationTherapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?
Girgis, C. M., Mokbel, N., & DiGirolamo, D. J. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0204-5 · Cited by 110
Hofmann, M., Schober-Halper, B., Oesen, S., Franzke, B., Tschan, H., Bachl, N., Strasser, E.-M., Quittan, M., Wagner, K.-H., & Wessner, B. (2016) · European Journal of Applied Physiology · doi:10.1007/s00421-016-3344-8 · Cited by 102
Tiano, J. P., Springer, D. A., & Rane, S. G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.617399 · Cited by 98
“With respect to SMAD3, the Food and Drug Administration recently granted Novartis a breakthrough therapy designation for their human anti-ActRII antibody (BYM338 or bimagrumab) that works by inhibiting the myostatin/activin type II receptor and preventing myostatin-induced pSMAD3 (65).”
BackgroundMyostatin and muscle atrophy during chronic kidney disease
Bataille, S., Chauveau, P., Fouque, D. P., Aparicio, M., & Koppe, L. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa129 · Cited by 103
Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Winbanks, C. E., Murphy, K. T., Bernardo, B. C., Qian, H., Liu, Y., Sepulveda, P. V., Beyer, C., Hagg, A., Thomson, R. E., Chen, J. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4976 · Cited by 95
Blocking extracellular activation of myostatin as a strategy for treating muscle wasting
Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, M. T., Salta, L., Long, K., McConaughy, W., Capili, A., Boston, C., Carven, G. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20524-9 · Cited by 94
Muscle Wasting Diseases: Novel Targets and Treatments
Furrer, R., & Handschin, C. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021041 · Cited by 103
“Even though blocking ActRII using BMY338 massively increased muscle mass in mice and prevented dexamethasone-induced muscle atrophy (54), the results in humans were less pronounced (55).”
Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy
Rooks, D. S., Laurent, D., Praestgaard, J., Rasmussen, S., Bartlett, M., & Tankó, L. B. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12205 · Cited by 90
“Recently published results in rodents and humans have highlighted the potential competitive advantages of ActRII involvement in the treatment of muscle wasting conditions.(23,24) The present observations add further support for a receptor antagonist by demonstrating the ability of bimagrumab to induce a rapid and mark…”
BackgroundMarceca, G. P., Londhe, P., & Calore, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00298 · Cited by 92
Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting
Henrot, P., Dupin, I., Schilfarth, P., Esteves, P., Blervaque, L., Zysman, M., Gouzi, F., Hayot, M., Pomiès, P., & Berger, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076454 · Cited by 96
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Li, C., Zhang, K., Pan, G., Ji, H., Li, C., Wang, X., Hu, X., Liu, R., Deng, L., Wáng, Y., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01915-9 · Cited by 84
“Based on our understanding of autophagy's physiological function, we now know that the basic level of autophagy and the stress-induced moderate autophagy may be important to maintain the cell metabolism[42,43].”
BackgroundAbati, E., Manini, A., Comi, G. P., & Corti, S. P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04408-w · Cited by 89
“Likewise, myostatin inhibition proved effective in halting muscle atrophy following steroid administration in mice [116, 117, 128].”
BackgroundSuh, J., Kim, N.-K., Lee, S.-H., Eom, J.-H., Lee, Y., Park, J.-C., Woo, K. M., Baek, J.-H., Kim, J.-E., Ryoo, H.-M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916034117 · Cited by 80
“Because of the well-established role of MSTN in skeletal muscle, blocking the MSTN signaling pathway has been adopted as a promising therapeutic strategy to prevent or reverse the loss of muscle mass and strength in patients with muscle wasting disorders (31, 32).”
Hatakeyama, S., Summermatter, S., Jourdain, M., Melly, S., Minetti, G. C., & Lach-Trifilieff, E. (2016) · Skeletal Muscle · doi:10.1186/s13395-016-0098-2 · Cited by 81
“In this report, the effect of a chimeric mouse version of bimagrumab (CDD866) [17], which retains the binding, selectivity, and potency profile of bimagrumab while reducing risk for immunogenicity and enabling longterm profiling studies in mice, was evaluated in a CT-26 mouse colon cancer cachexia model to clarify int…”
BackgroundSelf-citationReyes-Furrer, A. A., Andrade, S. D., Bachmann, D., Jeker, H., Steinmann, M., Accart, N., Dunbar, A., Rausch, M., Bono, E., Rimann, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02691-0 · Cited by 92
Blockade of ActRIIB Signaling Triggers Muscle Fatigability and Metabolic Myopathy
Relizani, K., Mouisel, E., Giannesini, B., Hourdé, C., Patel, K., Morales Gonzalez, S., Jülich, K., Vignaud, A., Piétri-Rouxel, F., Fortin, D., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.90 · Cited by 77
“This was done either through injection of sActRIIB-Fc 12,43 , AAV-mediated gene transfer 11 or antibodies directed against the ActRIIB receptor 44 .”
Fife, E., Kostka, J., Kroc, Ł., Guligowska, A., Pigłowska, M., Sołtysik, B., Kaufman-Szymczyk, A., Fabianowska-Majewska, K., & Kostka, T. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0888-y · Cited by 77
The TGF-β Signalling Network in Muscle Development, Adaptation and Disease
Chen, J. L., Colgan, T. D., Walton, K. L., Gregorevic, P., & Harrison, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-27511-6_5 · Cited by 88
High prevalence of inclusion body myositis in Norway; a population‐based clinical epidemiology study
Dobloug, G. C., Antal, E., Sveberg, L., Garen, T., Bitter, H., Stjärne, J., Grøvle, L., Gran, J. T., & Molberg, Ø. (2014) · European Journal of Neurology · doi:10.1111/ene.12627 · Cited by 74
“Nonetheless, with new and possibly efficient treatments being tested [29], it will be critical to identify sIBM cases earlier.”
BackgroundHeymsfield, S. B., Aronne, L. J., Montgomery, P., Klickstein, L. B., Coleman, L. A., Dole, K., Mindeholm, L., Spruill, S. E., Li, X., Attie, K. M., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04204-0 · Cited by 102
“Conversely, bimagrumab does not appear to affect food intake but primarily targets activin signaling in adipose tissue and skeletal muscle directly, leading to fat mass reduction and muscle growth 8,11,12 .”
Lack of evidence for GDF 11 as a rejuvenator of aged skeletal muscle satellite cells
Hinken, A. C., Powers, J. M., Luo, G., Holt, J. A., Billin, A. N., & Russell, A. J. (2016) · Aging Cell · doi:10.1111/acel.12475 · Cited by 71
“These data are consistent with the fact that GDF11 shares a high degree of sequence identity with GDF8, activates similar signaling pathways (Lach-Trifilieff et al., 2014), does not promote SC outgrowth, and reduces lean mass in mice.”
ResultNovel targeted therapies for cancer cachexia
Argilés, J. M. A., López-Soriano, F. J., Stemmler, B., & Busquets, S. (2017) · Biochemical Journal · doi:10.1042/bcj20170032 · Cited by 80
Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management
Siff, T. E., Parajuli, P., Razzaque, M. S., & Atfi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.03.007 · Cited by 77
The Skeletal Muscle as an Active Player Against Cancer Cachexia
Penna, F., Ballarò, R., Beltrà, M., Lucia, S. D., Garcia‐Castillo, L., & Costelli, P. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00041 · Cited by 78
“Similarly, Bimagrumab has proved effective in preventing muscle atrophy induced by glucocorticoids or cancer (Lach-Trifilieff et al., 2014; Hatakeyama et al., 2016).”
BackgroundAdvances in research on pharmacotherapy of sarcopenia
Feike, Y., Liu, Z., & Chen, W. (2021) · Aging Medicine · doi:10.1002/agm2.12168 · Cited by 82
Comparative Analysis of the Extracellular Matrix Proteome across the Myotendinous Junction
Jacobson, K. R., Lipp, S. N., Acuna, A., Leng, Y., Bu, Y., & Calve, S. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00248 · Cited by 69
A fully human transgene switch to regulate therapeutic protein production by cooling sensation
Bai, P., Liu, Y., Xue, S., Hamri, G. C., Saxena, P., Ye, H., Xie, M., & Fussenegger, M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0501-8 · Cited by 72
Principles of the activin receptor signaling pathway and its inhibition
Lodberg, A. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.04.001 · Cited by 62
Solagna, F., Tezze, C., Lindenmeyer, M. T., Lu, S. Y., Wu, G., Liu, S., Zhao, Y., Mitchell, R., Meyer, C., Omairi, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135821 · Cited by 68
The Fountain of Youth: A tale of parabiosis, stem cells, and rejuvenation
Conese, M., Carbone, A., Beccia, E., & Angiolillo, A. (2017) · Open Medicine · doi:10.1515/med-2017-0053 · Cited by 77
“[34] Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige”
BackgroundResultNovel myostatin-specific antibody enhances muscle strength in muscle disease models
Muramatsu, H., Kuramochi, T., Katada, H., Ueyama, A., Ruike, Y., Ohmine, K., Shida-Kawazoe, M., Miyano-Nishizawa, R., Shimizu, Y., Okuda, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81669-8 · Cited by 60
Therapeutic strategies against cancer cachexia
Argilés, J. M. A., López-Soriano, F. J., Stemmler, B., & Busquets, S. (2019) · European Journal of Translational Myology · doi:10.4081/ejtm.2019.7960 · Cited by 61
“When administered in association with glucocorticoids, BYM338 was able to prevent skeletal muscle mass loss and preserved muscle function, facilitating the recovery from muscle atrophy.(62) A humanized monoclonal antibody LY2495655 has been used in sarcopenic patients in a phase II trial, involving subjects who recent…”
BackgroundLee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019263117 · Cited by 59
“A second approach, which was taken by Novartis, was to develop a monoclonal antibody targeting ACVR2B directly (42 – 46).”
GDF11 and the Mythical Fountain of Youth
Brun, C. E., & Rudnicki, M. A. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.009 · Cited by 59
Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy
Saitoh, M., Ishida, J., Ebner, N., Anker, S. D., Springer, J., & von Haehling, S. (2017) · JCSM Clinical Reports · doi:10.17987/jcsm-cr.v2i1.37 · Cited by 57
Passey, S. L., Hansen, M. J., Bozinovski, S., McDonald, C. F., Holland, A. E., & Vlahos, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.013 · Cited by 61
“This strategy has worked well in cell culture and mouse models, where the ActRIIB antibody Bimagrumab (BYM338) effectively prevented the atrophic effects of myostatin and activin on cultured myotubes and caused muscle hypertrophy in mice (Lach-Trifilieff et al., 2014).”
BackgroundDevelopment of Novel Activin-Targeted Therapeutics
Chen, J. L., Walton, K. L., Al-Musawi, S. L., Kelly, E. K., Qian, H., La, M., Lu, L., Lovrecz, G., Ziemann, M., Lazarus, R., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.221 · Cited by 54
Rooks, D., Petricoul, O., Praestgaard, J., Bartlett, M., Laurent, D., & Roubenoff, R. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12639 · Cited by 54
Novel therapeutic options for cachexia and sarcopenia
Molfino, A., Amabile, M. I., Rossi Fanelli, F., & Muscaritoli, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1208168 · Cited by 54
“The modulation of activin receptor II (ActRII) B, which regulates myostatin signaling [31,32], causes muscle atrophy, while a blockade of this”
BackgroundThe Potential to Fight Obesity with Adipogenesis Modulating Compounds
Zhao, J., Zhou, A., & Qi, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042299 · Cited by 61
“Lead to significant loss of total body fat mass and metabolic improvement in overweight patients with type 2 diabetes [64].”
BackgroundMastaitis, J. W., Gomez, D., Raya, J. G., Li, D., Min, S., Stec, M., Kleiner, S., McWilliams, T., Altarejos, J. Y., Murphy, A. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59485-9 · Cited by 53
“Prior research into the mechanisms that regulate muscle mass in adults have highlighted the importance of the ActRIIA/B receptor systems, as blocking these receptors can result in profound muscle growth in adult animals and humans 19,21,22 .”
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
Nielsen, T. L., Vissing, J., & Krag, T. O. B. (2021) · Cells · doi:10.3390/cells10030533 · Cited by 60
Davey, J. R., Watt, K. I., Parker, B. L., Chaudhuri, R., Ryall, J. G., Cunningham, L., Qian, H., Sartorelli, V., Sandri, M., Chamberlain, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85477 · Cited by 51
“The identification of specific TGF-β family members that negatively impact on muscle attributes via ACTR2BSMAD2/3 and that are associated with conditions of frailty has stimulated considerable interest in the development of therapies to target these ligands and the processes they regulate in muscle (17, 22, 23).”
BackgroundIskenderian, A., Liu, N., Deng, Q., Huang, Y. L., Shen, C., Palmieri, K. J., Crooker, R., Lundberg, D. M., Kastrapeli, N., Pescatore, B., et al. (2018) · Skeletal Muscle · doi:10.1186/s13395-018-0180-z · Cited by 59
Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 54
The Orphan Nuclear Receptor Nur77 Is a Determinant of Myofiber Size and Muscle Mass in Mice
Tontonoz, P., Cortez-Toledo, O., Wroblewski, K., Hong, C., Lim, L., Carranza, R., Conneely, O., Metzger, D., & Chao, L. C. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00715-14 · Cited by 49
“performed as described previously (28).”
New insights into the treatment of myositis
Glaubitz, S., Zeng, R., & Schmidt, J. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19886494 · Cited by 53
Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment
Schmidt, K., & Schmidt, J. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000436 · Cited by 49
Development of Pharmacotherapies for the Treatment of Sarcopenia
Rooks, D., & Roubenoff, R. (2019) · The Journal of Frailty & Aging · doi:10.14283/jfa.2019.11 · Cited by 46
“Postpartum blockade of myostatin activity in animals and humans by either direct action on the ligand (111-115) or receptor antagonism (108, 109, 116, 117) is associated with varying degrees of muscle hypertrophy, and less frequently with clinically meaningful improvement in physical function (117).”
InfluentialPermpoon, U., Moon, J., Kim, C. Y., & Nam, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157616 · Cited by 241
Effect of Bimagrumab on Body Composition: A Systematic Review and Meta-Analysis
Kanbay, M., Siriopol, D., Copur, S., Hasbal, N. B., Güldan, M., Kalantar-Zadeh, K., Garfias-Veitl, T., & von Haehling, S. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02825-4 · Cited by 45
“Its effects are thought to result from the attenuation of negative regulators of muscle mass, such as myostatin [6, 7].”
Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration
Cohen, T. V., Kollias, H. D., Liu, N., Ward, C. W., & Wagner, K. R. (2015) · The Journal of Physiology · doi:10.1113/jp270201 · Cited by 47
“Although TGF-β predominantly binds to TGF-β type II receptor, myostatin shows preferential binding affinity to the activin type IIB receptor (ActRIIB) (Lee & McPherron, 2001; Rebbapragada et al. 2003).”
BackgroundInfluentialSporadic inclusion body myositis – a myodegenerative disease or an inflammatory myopathy
Weihl, C. C., & Mammen, A. L. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12384 · Cited by 48
Activin A: an emerging target for improving cancer treatment?
Ries, A., Schelch, K., Falch, D., Pany, L., Hoda, M. A., & Grusch, M. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1799350 · Cited by 53
“body that binds both ActRIIA and IIB and leads to muscle hypertrophy in experimental animal models [111].”
BackgroundThevis, M., & Schänzer, W. (2016) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7470 · Cited by 49
“Complementary to myostatin-binding/neutralizing agents, the utility of myostatin-receptor blocking drugs such as BYM338 (bimagrumab) has been explored, which further expands the need for flexible test methods.([79]) None of these”
BackgroundCancer-Associated Cachexia: A Systemic Consequence of Cancer Progression
Biswas, A., & Acharyya, S. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033642 · Cited by 47
“Bimagrumab is a human anti-ACVR2 antibody that prevents the binding of the ACVR2 ligands to their receptors (Lach-Trifilieff et al. 2014).”
BackgroundHoogaars, W. M. H., & Jaspers, R. T. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_8 · Cited by 45
Amato, A. A., Hanna, M. G., Machado, P., Badrising, U. A., Chinoy, H., Benvéniste, O., Karanam, A. K., Wu, M., Tankó, L. B., Schubert-Tennigkeit, A. A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011626 · Cited by 48
“, activin andmyostatin) to these receptors, thereby inhibiting downstream signaling-induced muscle loss.(7,8)”
BackgroundSkeletal muscle dysfunction with advancing age
Pabla, P., Jones, E. J., Piasecki, M., & Phillips, B. E. (2024) · Clinical Science · doi:10.1042/cs20231197 · Cited by 55
Phase II drugs that are currently in development for the treatment of cachexia
Dingemans, A.-M. C., de Vos-Geelen, J., Langen, R., & Schols, A. M. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.942729 · Cited by 41
“In mouse models, it has been shown that BYM338 inhibits myostatin and the activin signaling in skeletal myoblasts and myotubes [79].”
Metadata
- Authors
- Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D. J.
- Affiliations
- MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Novartis (Switzerland) (CH)
- Development and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
- Novartis Institutes for BioMedical Research (CH)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2014-02-01
- Volume
- 34
- Issue
- 4
- Pages
- 606-618
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3911487
- OpenAlex
- W2102107385
- Semantic Scholar
- 9ec58206f235e018d6953a27e975ae19a1c51271
- Cited by
- 306
- References
- 58
- Citations by year
- 2026: 22 · 2025: 16 · 2024: 19 · 2023: 21 · 2022: 20 · 2021: 37 · 2020: 29 · 2019: 28 · 2018: 25 · 2017: 18 · 2016: 29 · 2015: 21 · 2014: 19
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- MorphoSys
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- activin type II receptor, bimagrumab, myostatin, skeletal muscle hypertrophy, muscle atrophy, Smad2/3 phosphorylation, skeletal myoblast differentiation, activin A, GDF11, muscle weakness, myosin heavy chain degradation, muscle mass regulation
- MeSH terms
- Animals, Antibodies, Monoclonal, Atrophy, Cell Differentiation, Humans, Hypertrophy, Signal Transduction, Muscle, Skeletal, Antibodies, Blocking, Activins, Activin Receptors, Type II, Myoblasts, Skeletal, Mice, Smad2 Protein, Smad3 Protein, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.